TVRD insider transaction filings
Tvardi Therapeutics, Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-11. Screen TVRD transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | Shiff Susan Ph.D. — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | HALL WALLACE L JR — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Smith Cynthia — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Shah Sujal — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Conn Avi Daniel — Chief Financial Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | O'Brien Stephen Paul — Principal Accounting Officer | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Alibhai Imran Nizamudin — Chief Executive Officer, Director | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Kauh John Saewook M.D. — Chief Medical Officer | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Conn Avi Daniel — Chief Financial Officer | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | O'Brien Stephen Paul — Principal Accounting Officer | Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Alibhai Imran Nizamudin — Chief Executive Officer, Director | Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Kauh John Saewook M.D. — Chief Medical Officer | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Tweardy Samuel David — 10% owner | Other (J): 315,658 @ $0 · Other (J): 315,658 @ $0 | EDGAR |
| 2025-05-02 | 4/A | HALL WALLACE L JR — Director | Grant/award (A): 44,712 · Grant/award (A): 202,044 | EDGAR |
| 2025-05-02 | 4/A | Wirk Shaheen — Director | Grant/award (A): 176,030 · Grant/award (A): 263,164 | EDGAR |
| 2025-04-21 | 4 | Larson Jeffrey Leroy — SVP, Research & Development | Grant/award (A): 10,820 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | O'Brien Stephen Paul — Principal Accounting Officer | Grant/award (A): 7,213 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Chen Yixin — VP, Chem, Mfg and Ctrls | Grant/award (A): 7,213 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Conn Avi Daniel — Chief Financial Officer | Grant/award (A): 43,547 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Kauh John Saewook M.D. — Chief Medical Officer | Grant/award (A): 36,210 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Alibhai Imran Nizamudin — Chief Executive Officer, Director | Grant/award (A): 182,320 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Shiff Susan Ph.D. — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Wirk Shaheen — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Smith Cynthia — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Shah Sujal — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | HALL WALLACE L JR — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-04-17 | 4 | O'Brien Stephen Paul — Principal Accounting Officer | Grant/award (A): 11,399 (derivative) · Grant/award (A): 3,352 (derivative) | EDGAR |
| 2025-04-17 | 4 | HALL WALLACE L JR — Director | Other (J): 44,712 · Other (J): 202,044 | EDGAR |
| 2025-04-17 | 4 | Kauh John Saewook M.D. — Chief Medical Officer | Grant/award (A): 74,049 (derivative) | EDGAR |
| 2025-04-17 | 4 | Chen Yixin — VP, Chem, Mfg and Ctrls | Grant/award (A): 14,752 (derivative) | EDGAR |
| 2025-04-17 | 4 | Wirk Shaheen — Director | Grant/award (A): 4,191 · Other (J): 176,030 · Other (J): 263,164 · Grant/award (A): 2,011 (derivative) | EDGAR |
| 2025-04-17 | 4 | Shah Sujal — Director | Grant/award (A): 10,394 (derivative) · Grant/award (A): 8,047 (derivative) | EDGAR |
| 2025-04-17 | 4 | Larson Jeffrey Leroy — SVP, Research & Development | Grant/award (A): 16,764 (derivative) · Grant/award (A): 5,364 (derivative) | EDGAR |
| 2025-04-17 | 4 | Conn Avi Daniel — Chief Financial Officer | Grant/award (A): 89,053 (derivative) | EDGAR |
| 2025-04-17 | 4 | Alibhai Imran Nizamudin — Chief Executive Officer, Director | Grant/award (A): 207,881 (derivative) · Grant/award (A): 2,011 (derivative) · Grant/award (A): 160,940 (derivative) | EDGAR |
| 2025-04-17 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 18,441 (derivative) | EDGAR |
Recent 8-K events — Tvardi Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TVRD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →